On safety margin for drug interchangeability.

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Drug Regulatory Affairs
• Pharmaceutical Sciences

Background:

• Increasing availability of generic and biosimilar drugs raises concerns about their safety, efficacy, and interchangeability with originator products.
• Current regulatory frameworks, like the U.S. Food and Drug Administration (FDA) guidelines, permit generic/biosimilar substitution without mandatory bioequivalence/biosimilarity re-assessment for each product.
• Interchangeable drug use is common practice, yet lacks robust safety monitoring mechanisms.

Purpose of the Study:

• To address safety concerns regarding interchangeable generic and biosimilar drugs.
• To propose an adjusted bioequivalence (or biosimilarity) limit for enhanced safety monitoring.
• To develop safety margins for monitoring drug interchangeability by minimizing response variability during product switching.

Main Methods:

• Analysis of existing bioequivalence (or biosimilarity) assessment criteria.
• Adjustment of current bioequivalence limits based on observed geometric mean ratios and variability.
• Development of safety margins for monitoring the relative change in drug response with and without switching.

Main Results:

• Proposed adjusted bioequivalence limits to enhance the safety of interchangeable generic and biosimilar drugs.
• A framework for developing safety margins to monitor drug interchangeability.
• Methodology to minimize relative changes in therapeutic response when switching between drug products.

Conclusions:

• Current bioequivalence standards may not fully guarantee the safety of interchangeable drug products.
• Adjusted bioequivalence limits and safety margins are crucial for ensuring patient safety with generic and biosimilar drug use.
• Implementing these adjustments can improve the monitoring of drug interchangeability and minimize risks associated with switching medications.